Stock DRTS ALPHA TAU MEDICAL LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Alpha Tau Medical Ltd.

Equities

DRTS

IL0011839383

Real-time Estimate Cboe BZX
Other stock markets
 16:33:59 22/05/2024 BST 		5-day change 1st Jan Change
2.625 USD -3.14% Intraday chart for Alpha Tau Medical Ltd. 0.00% -11.96%
05-06 Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow CI
03-07 Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow
Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Alpha Tau Medical Ltd. Announces Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
Alpha Tau, HekaBio Seek Japan's Premarket Approval of Alpha-Radiation Therapy for Head, Neck Cancer
Alpha Tau Medical Ltd. Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
Alpha Tau Medical Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Alpha Tau Medical Ltd. Announces Stephen M. Hahn Joins Scientific Advisory Board
Alpha Tau Medical Treats First Patient With Advanced Inoperable Pancreatic Cancer in Israel Clinical Trial
Alpha Tau Medical Ltd. Treats First Patient with Advanced Inoperable Pancreatic Cancer At Israel's Hadassah Medical Center
Alpha Tau Medical Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Alpha Tau Medical Says Alpha DaRT Shows Long-Term Safety, Tumor Control Outcomes for Cancer Patients From Multiple Trials
Traders on Edge Amid Elevated Bond Yields, Driving Premarket Losses for US Equity Futures
Top Premarket Gainers
Alpha Tau Medical Ltd. Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT
Alpha Tau Medical Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Alpha Tau Medical Ltd. Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University
Alpha Tau Medical Ltd. and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial
Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Alpha Tau Medical Ltd. Announces Alpha DaRT Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer Trial
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DRTS Stock
  4. News Alpha Tau Medical Ltd.
  5. Other languages